On this page
- Regulatory status first
- Evidence category map
- Who this is for
- What the evidence can support
- What remains uncertain
- Verification steps
- Risks, red flags, and limits
- Sources
- Evidence and status are separate questions
- Evidence used on this page
- Continue the evidence path
- The combination problem
- Two marketed names create more—not less—uncertainty
CJC-1295 and Ipamorelin: Claims, Evidence, and Safety Gaps
A compound-specific reality check for growth-hormone secretagogue marketing.1
Regulatory status first
CJC-1295 and ipamorelin are not established general-purpose longevity or body-composition treatments.1 Available human data are limited, and FDA materials identify safety and characterization concerns relevant to compounding.12
Evidence category map
Who this is for
Women navigating midlife health decisions and the clinicians or reviewers helping them evaluate evidence and uncertainty.
What the evidence can support
- Some human pharmacology research exists for defined compounds and protocols.
- FDA has described serious adverse events or data limitations.12
- Product-specific approval status can be verified.1
What remains uncertain
- Long-term benefit-risk in generally healthy women is unknown.1
- Combination dosing and real-world product identity are uncertain.
- Menopause-specific outcomes are not established.
Verification steps
- Separate the two compounds and every claimed endpoint.
- Verify whether data used the marketed route and formulation.
- Ask what safer approved or non-drug alternatives address the goal.
Risks, red flags, and limits
Sources
Evidence and status are separate questions
| Layer | Question | Common category error |
|---|---|---|
| Product status | Is the exact product approved, compounded, investigational or sold for research? | Treating a facility, ingredient or trial as product approval |
| Human evidence | Do trials match the molecule, route, population and claimed outcome? | Generalizing from animals, another peptide or another route |
| Quality | What identity, batch, sterility and endotoxin evidence exists? | Using analytical purity as a synonym for sterile or safe |
| Personal decision | What established alternatives, risks and monitoring questions matter? | Letting an online claim replace qualified care |
This publication provides no dose, cycle, injection technique, seller ranking or procurement path for unapproved investigational products.12
Claim-level source ledger
Evidence used on this page
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Checked 2026-08-25.
- Internal Error (). Checked 2026-08-25.
Interpretation boundary: each source is listed for the statement it supports; population and design limits remain visible.
The combination problem
When two active substances are marketed together, changes and adverse events cannot be cleanly assigned without an appropriate study.1 This page now links to the standalone ipamorelin review so readers can separate compound-specific status from combination claims.1
Two marketed names create more—not less—uncertainty
A combination claim needs evidence for the exact pair, formulation, route and outcome.1 Evidence for a growth-hormone-releasing hormone analogue does not automatically transfer to a ghrelin-receptor agonist; evidence for either component alone does not prove the marketed stack.1
| Evidence found | What may be inferred | What remains unanswered |
|---|---|---|
| Mechanism for one component | A biological pathway may be plausible | Net clinical benefit, interaction and long-term harm |
| Human data for one component | That product and protocol produced the reported result | Effect of the combination or a different seller’s product |
| Biomarker change | A laboratory measure changed | Function, symptoms, healthy aging or risk–benefit |
| Seller protocol | The marketing proposition is visible | Approval, evidence, sterile quality or medical suitability |